The radiotherapy process is at a turning point. No more long and exhausting cycles: the administration of the treatment in the future will take place in the opetoria room in a single session. The clinical data of the new BAT-90 radiotherapy are promising and open important prospects for nuclear medicine in oncology, for improving the quality of life and patient outcomes.

L‘agency BetaGlue Technologies announces the treatment of first patient with BAT-90the new anticancer radiotherapy developed by the Company. The first patient with liver cancer recruited from the trial was subjected to the administration of microspheres labeled with Yttrium 90 inside the tumor mass using a syringe-like device. These microspheres, held in the injection area from a fast-curing biocompatible glue (120 seconds), they release radiant energy only in the target tumor. The glue prevents radiation from migrating to other organs or tissues.

How profitable is it?

BAT-90 releases ionizing radiation (i.e. energy) in same quantities as traditional radiotherapybut without crossing the human body from the outside. During the operation, the microspheres are administered inside the mass or on the margin of the surgical tumor resection. BAT-90 is an extremely nuclear medicine solution precise (affects only the area affected by the tumor), quick (one administration only) e safe (the energy is brought where it is needed, avoiding irradiation of neighboring organs and tissues). There are no studies yet to compare head-to-head efficacy with traditional radiotherapy. They will be led into the step 3 of the clinical study.

Benefits for the patient

BAT-90 also brings significant psycho-physical benefits to the patient totally reducing the therapeutic path. In areas where adequate health facilities are lacking, or are not easily accessible, i patients they are often forced to dedicate one important part of their time to travel. For the breast cancerfor example, the cycle and of about 6 weeks of radiotherapy. With Bat-90 the patients in a single treatment would be able to drastically reduce the repercussions of the treatments on private and working life. This new formula one shot has the advantage of eliminating access barriers to hospitals, with a economic advantage also for the sanitary system. THE patients they could also save money on the cost of numerous trips to undergo the courses of treatment traditional.

Early stage breast cancer: new techniques

X

Clinical studies

Currently BetaGlue Technologies is leading two Phase I / II clinical trials with BAT-90 on patients with primary neoplasm of the liver and in patients with breast cancer in the initial phase. Studies are ongoing at New Hospitals of Tbilisi in Georgia and are coordinated by prof. Malkhaz Mizandaripresident of the GACIR (Georgian Association of Cardiovascular and Interventetional Radiology). «BAT-90 allows you to use a access much smoother and ultrasound-guided for intra-tumor initiation“- he says -” in all probability it should be accepted as thetherapeutic option for inoperable liver tumors“. The confirmations of efficacy and safety of the first studies represent excellent news for patients, oncologists and radiotherapists: “The results on this first patient open important perspectives for therapeutic nuclear medicine “- he says Antonino AmatoCEO of BetaGlue Technologies – «with this treatment the concept from precision medicine in radiotherapy“.

iO Donna © REPRODUCTION RESERVED

The article The new anticancer radiotherapy: the breakthrough for liver and breast cancer seems to be the first on iO Donna.

ttn-13